Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia

Journal of Infection

Volumn 55, Issue 5, 2007, Pages 400-407

  Prat, Cristina ^a,b,c   Lacoma, Alicia ^a,b   Dominguez, Josep ^a,b,c   Papassotiriou, Jana ^d   Morgenthaler, Nils G ^d   Andreo, Felipe ^a,b,c   Tudela, Pere ^a   Ruiz Manzano, Juan ^a,b,c   Ausina, Vicente ^a,b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d BRAHMS AG   (Germany)

Author keywords

Complications; CURB 65; MR proANP; Pneumonia; Pneumonia Severity Index

Indexed keywords

ANTIBIOTIC AGENT; ATRIAL NATRIURETIC FACTOR;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; THORAX RADIOGRAPHY; UNIVERSITY HOSPITAL;

AGED; ATRIAL NATRIURETIC FACTOR; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LUNG; MALE; PNEUMONIA; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 35348971859     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.07.018     Document Type: Article

References (28)

1. Fine M.J., Auble T.E., Yealy T.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
2. Lim W.S., van der Eerden M.M., Laing R., Boersma W.G., Karalus N., Town G.I., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 5 (May 2003) 377-382
3. Prat C., Dominguez J., Andreo F., Blanco S., Pallares A., Cuchillo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 52 3 (Mar 2006) 169-177
4. Muller B., and Prat C. Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. Clin Microbiol Infect 12 Suppl. 9 (Dec 2006) 8-16
5. Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M.M., Huber P.R., Tamm M., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363 9409 (Feb 21 2004) 600-607
6. Christ-Crain M., Stolz D., Bingisser R., Muller C., Miedinger D., Huber P.R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174 1 (Jul 1 2006) 84-93
7. Luyt C.E., Guerin V., Combes A., Trouillet J.L., Ayed S.B., Bernard M., et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171 1 (Jan 1 2005) 48-53
8. Beishuizen A., Hartemink K.J., Vermes I., and Groeneveld A.J. Circulating cardiovascular markers and mediators in acute illness: an update. Clin Chim Acta 354 1-2 (Apr 2005) 21-34
9. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 5 (Jul 30 1998) 321-328
10. Rosenzweig A., and Seidman C.E. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 60 (1991) 229-255
11. Cappellin E., Gatti R., Spinella P., De Palo C.B., Woloszczuk W., Maragno I., et al. Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation?. Clin Chim Acta 310 1 (Aug 1 2001) 49-52
12. Morgenthaler N.G., Struck J., Thomas B., and Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50 1 (Jan 2004) 234-236
13. Coonrod J.D., and Rytel M.W. Detection of type-specific pneumococcal antigens by counterimmunoelectrophoresis. I. Methodology and immunologic properties of pneumococcal antigens. J Lab Clin Med 81 5 (May 1973) 770-777
14. Coonrod J.D., and Rytel M.W. Detection of type-specific pneumococcal antigens by counterimmunoelectrophoresis. II. Etiologic diagnosis of pneumococcal pneumonia. J Lab Clin Med 81 5 (May 1973) 778-786
15. Hopstaken R.M., Witbraad T., van Engelshoven J.M., and Dinant G.J. Inter-observer variation in the interpretation of chest radiographs for pneumonia in community-acquired lower respiratory tract infections. Clin Radiol 59 8 (Aug 2004) 743-752
16. Dominguez J., Blanco S., Rodrigo C., Azuara M., Galí N., Mainou A., et al. Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children. J Clin Microbiol 41 5 (May 2003) 2161-2163
17. Aronsky D., and Haug P.J. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc 7 1 (Jan-Feb 2000) 55-65
18. Boussekey N., Leroy O., Georges H., Devos P., d'Escrivan T., and Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 33 4 (Aug 2005) 257-263
19. Prat C., Dominguez J., Rodrigo C., Gimenez M., Azuara M., Jimenez O., et al. Procalcitonin C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J 22 11 (Nov 2003) 963-968
20. Muller B., Suess E., Schuetz P., Muller C., Bingisser R., Bergmann A., et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 260 6 (Dec 2006) 568-576
21. Wilkins M.R., Redondo J., and Brown L.A. The natriuretic-peptide family. Lancet 349 9061 (May 3 1997) 1307-1310
22. Mueller C., Laule-Kilian K., Scholer A., and Perruchoud A.P. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 258 4 (Oct 2005) 391-393
23. Ala-Kopsala M., Magga J., Peuhkurinen K., Leipala J., Ruskoaho H., Leppaluoto J., et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A-B-type natriuretic peptides. Clin Chem 50 9 (Sep 2004) 1576-1588
24. Gegenhuber A., Struck J., Poelz W., Pacher R., Morgenthaler N.G., Bergmann A., et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 52 5 (May 2006) 827-831
25. Morgenthaler N.G., Struck J., Christ-Crain M., Bergmann A., and Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 9 1 (Feb 2005) R37-R45
26. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25 6 (Jun 1999) 556-566
27. Eichacker P.Q., Parent C., Kalil A., Esposito C., Cui X., Banks S.M., et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166 9 (Nov 1 2002) 1197-1205
28. Simon L., Gauvin F., Amre D.K., Saint-Louis P., and Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39 2 (Jul 15 2004) 206-217